{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/101696"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/101696","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Characterization of the anti-type I interferon effects of the cellular flice-like inhibitory protein (CFLIP)","abstract":"The cellular FLICE-like inhibitory protein (cFLIP) is well known as a major immunomodulatory protein. Various works have described its role in major cellular pathways such as apoptosis, autophagy, necroptosis, NF-KB regulation and more recently, modulation of interferon responses. Interferon alpha (IFNa) and interferon beta (IFNb) are in the class of type I IFN and are critical as the first line of defense against viral infection. Interestingly, these IFNs also maintain roles apart from viral infection including participating in the pathophysiology of tumor biology and autoimmunity. Previous studies found that cFLIPL could inhibit IFNb production. My work demonstrated that this was by inhibiting the major transcription factor for IFNb expression, interferon regulatory factor 3 (IRF3). Mutational analysis revealed that the CLD within the C-terminus of cFLIPL is responsible for inhibiting IRF3-CBP-DNA interactions. Further, when cFLIPL was knocked down in various tumor cell lines, levels of tumor protective interferon stimulated genes (ISGs) increased, suggesting cFLIPL may contribute to tumorigenesis by way of inhibiting IRF3. In addition, cFLIPL also inhibited IFNa production by inhibiting the transcription factor, IRF7. In this case, the CLD of cFLIPL was dispensable to inhibit IFNa production; an alternative shorter isoform, cFLIPS, which lacks the CLD, also inhibited IRF7-induced IFNa expression. IRF7 phosphorylation was greatly reduced in cells expressing cFLIPL and cFLIPS. I hypothesized cFLIP targeted the IKK kinase. In support of this hypothesis, I found that cFLIPL co-IPs with IKa and IKKa-IRF7 interactions were disrupted in the presence of cFLIPL. These interactions were confirmed in a pDC-like cell line overexpressing cFLIP, suggesting that the mechanism by which cFLIP inhibits IFN production is physiologically relevant. Taken together, these data suggest that cFLIP is a major regulator of type I IFNs. It is of major clinical interest to regard the regulation of type I IFN expression by cFLIP when considering the pathophysiology behind diseases like cancer and autoimmunity.","abstract_html":"The cellular FLICE-like inhibitory protein (cFLIP) is well known as a major immunomodulatory protein. Various works have described its role in major cellular pathways such as apoptosis, autophagy, necroptosis, NF-KB regulation and more recently, modulation of interferon responses. Interferon alpha (IFNa) and interferon beta (IFNb) are in the class of type I IFN and are critical as the first line of defense against viral infection. Interestingly, these IFNs also maintain roles apart from viral infection including participating in the pathophysiology of tumor biology and autoimmunity. Previous studies found that cFLIPL could inhibit IFNb production. My work demonstrated that this was by inhibiting the major transcription factor for IFNb expression, interferon regulatory factor 3 (IRF3). Mutational analysis revealed that the CLD within the C-terminus of cFLIPL is responsible for inhibiting IRF3-CBP-DNA interactions. Further, when cFLIPL was knocked down in various tumor cell lines, levels of tumor protective interferon stimulated genes (ISGs) increased, suggesting cFLIPL may contribute to tumorigenesis by way of inhibiting IRF3. In addition, cFLIPL also inhibited IFNa production by inhibiting the transcription factor, IRF7. In this case, the CLD of cFLIPL was dispensable to inhibit IFNa production; an alternative shorter isoform, cFLIPS, which lacks the CLD, also inhibited IRF7-induced IFNa expression. IRF7 phosphorylation was greatly reduced in cells expressing cFLIPL and cFLIPS. I hypothesized cFLIP targeted the IKK kinase. In support of this hypothesis, I found that cFLIPL co-IPs with IKa and IKKa-IRF7 interactions were disrupted in the presence of cFLIPL. These interactions were confirmed in a pDC-like cell line overexpressing cFLIP, suggesting that the mechanism by which cFLIP inhibits IFN production is physiologically relevant. Taken together, these data suggest that cFLIP is a major regulator of type I IFNs. It is of major clinical interest to regard the regulation of type I IFN expression by cFLIP when considering the pathophysiology behind diseases like cancer and autoimmunity.","abstract_has_math":false,"creators":["Gates-Tanzer, Lauren Taylor"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Microbiology","degree_department":null,"school":null,"contributors":["Shisler, Joanna","Blanke, Steven","Vanderpool, Cari","Wilson, Brenda"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-09-27T16:30:29Z","date_published":"2018-09-27T16:30:29Z","updated_at":"2026-07-22T22:24:40Z","subjects":["cFLIP","interferon, innate","immunity"],"languages":["en"],"rights":["Copyright 2018 Lauren Taylor Gates-Tanzer"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/101696","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Shisler, Joanna","Blanke, Steven","Vanderpool, Cari","Wilson, Brenda"]},{"key":"dc:creator","label":"Author","values":["Gates-Tanzer, Lauren Taylor"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-09-27T16:30:29Z","2020-09-28T09:15:16Z","2018-07-11","2018-08"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Microbiology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["cFLIP","interferon, innate","immunity"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2018 Lauren Taylor Gates-Tanzer"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/101696"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The cellular FLICE-like inhibitory protein (cFLIP) is well known as a major immunomodulatory protein. Various works have described its role in major cellular pathways such as apoptosis, autophagy, necroptosis, NF-KB regulation and more recently, modulation of interferon responses. Interferon alpha (IFNa) and interferon beta (IFNb) are in the class of type I IFN and are critical as the first line of defense against viral infection. Interestingly, these IFNs also maintain roles apart from viral infection including participating in the pathophysiology of tumor biology and autoimmunity. Previous studies found that cFLIPL could inhibit IFNb production. My work demonstrated that this was by inhibiting the major transcription factor for IFNb expression, interferon regulatory factor 3 (IRF3). Mutational analysis revealed that the CLD within the C-terminus of cFLIPL is responsible for inhibiting IRF3-CBP-DNA interactions. Further, when cFLIPL was knocked down in various tumor cell lines, levels of tumor protective interferon stimulated genes (ISGs) increased, suggesting cFLIPL may contribute to tumorigenesis by way of inhibiting IRF3. In addition, cFLIPL also inhibited IFNa production by inhibiting the transcription factor, IRF7. In this case, the CLD of cFLIPL was dispensable to inhibit IFNa production; an alternative shorter isoform, cFLIPS, which lacks the CLD, also inhibited IRF7-induced IFNa expression. IRF7 phosphorylation was greatly reduced in cells expressing cFLIPL and cFLIPS. I hypothesized cFLIP targeted the IKK kinase. In support of this hypothesis, I found that cFLIPL co-IPs with IKa and IKKa-IRF7 interactions were disrupted in the presence of cFLIPL. These interactions were confirmed in a pDC-like cell line overexpressing cFLIP, suggesting that the mechanism by which cFLIP inhibits IFN production is physiologically relevant. Taken together, these data suggest that cFLIP is a major regulator of type I IFNs. It is of major clinical interest to regard the regulation of type I IFN expression by cFLIP when considering the pathophysiology behind diseases like cancer and autoimmunity.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2020-08-01","The student, Lauren Gates-Tanzer, accepted the attached license on 2018-07-10 at 14:24.","The student, Lauren Gates-Tanzer, submitted this Dissertation for approval on 2018-07-10 at 14:35.","This Dissertation was approved for publication on 2018-07-11 at 11:08.","DSpace SAF Submission Ingestion Package generated from Vireo submission #12800 on 2018-09-27 at 11:18:45","Made available in DSpace on 2018-09-27T16:30:29Z (GMT). No. of bitstreams: 3 GATES-TANZER-DISSERTATION-2018.pdf: 6091493 bytes, checksum: 1697a4721275de3936a02dde2bdb83ab (MD5) Gates Final Doctoral Thesis.docx: 3206686 bytes, checksum: 1ed27cb589518d0f4445cf3c4c50b9d6 (MD5) LICENSE.txt: 4216 bytes, checksum: fb3209bc92839bcc365561fffe2e5c7b (MD5) Previous issue date: 2018-07-11","Embargo set by: Seth Robbins for item 107794 Lift date: 2020-09-27T16:30:34Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107794 Lift date: 2020-09-27T16:31:43Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107794 Lift date: 2020-09-27T16:34:29Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only Restriction Lifted for Item 107794 on 2020-09-28T09:15:16Z."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Characterization of the anti-type I interferon effects of the cellular flice-like inhibitory protein (CFLIP)"]}]}],"canonical_facts":{"dc:contributor":["Shisler, Joanna","Blanke, Steven","Vanderpool, Cari","Wilson, Brenda"],"dc:creator":["Gates-Tanzer, Lauren Taylor"],"dc:date":["2018-09-27T16:30:29Z","2020-09-28T09:15:16Z","2018-07-11","2018-08"],"dc:description":["The cellular FLICE-like inhibitory protein (cFLIP) is well known as a major immunomodulatory protein. Various works have described its role in major cellular pathways such as apoptosis, autophagy, necroptosis, NF-KB regulation and more recently, modulation of interferon responses. Interferon alpha (IFNa) and interferon beta (IFNb) are in the class of type I IFN and are critical as the first line of defense against viral infection. Interestingly, these IFNs also maintain roles apart from viral infection including participating in the pathophysiology of tumor biology and autoimmunity. Previous studies found that cFLIPL could inhibit IFNb production. My work demonstrated that this was by inhibiting the major transcription factor for IFNb expression, interferon regulatory factor 3 (IRF3). Mutational analysis revealed that the CLD within the C-terminus of cFLIPL is responsible for inhibiting IRF3-CBP-DNA interactions. Further, when cFLIPL was knocked down in various tumor cell lines, levels of tumor protective interferon stimulated genes (ISGs) increased, suggesting cFLIPL may contribute to tumorigenesis by way of inhibiting IRF3. In addition, cFLIPL also inhibited IFNa production by inhibiting the transcription factor, IRF7. In this case, the CLD of cFLIPL was dispensable to inhibit IFNa production; an alternative shorter isoform, cFLIPS, which lacks the CLD, also inhibited IRF7-induced IFNa expression. IRF7 phosphorylation was greatly reduced in cells expressing cFLIPL and cFLIPS. I hypothesized cFLIP targeted the IKK kinase. In support of this hypothesis, I found that cFLIPL co-IPs with IKa and IKKa-IRF7 interactions were disrupted in the presence of cFLIPL. These interactions were confirmed in a pDC-like cell line overexpressing cFLIP, suggesting that the mechanism by which cFLIP inhibits IFN production is physiologically relevant. Taken together, these data suggest that cFLIP is a major regulator of type I IFNs. It is of major clinical interest to regard the regulation of type I IFN expression by cFLIP when considering the pathophysiology behind diseases like cancer and autoimmunity.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2020-08-01","The student, Lauren Gates-Tanzer, accepted the attached license on 2018-07-10 at 14:24.","The student, Lauren Gates-Tanzer, submitted this Dissertation for approval on 2018-07-10 at 14:35.","This Dissertation was approved for publication on 2018-07-11 at 11:08.","DSpace SAF Submission Ingestion Package generated from Vireo submission #12800 on 2018-09-27 at 11:18:45","Made available in DSpace on 2018-09-27T16:30:29Z (GMT). No. of bitstreams: 3 GATES-TANZER-DISSERTATION-2018.pdf: 6091493 bytes, checksum: 1697a4721275de3936a02dde2bdb83ab (MD5) Gates Final Doctoral Thesis.docx: 3206686 bytes, checksum: 1ed27cb589518d0f4445cf3c4c50b9d6 (MD5) LICENSE.txt: 4216 bytes, checksum: fb3209bc92839bcc365561fffe2e5c7b (MD5) Previous issue date: 2018-07-11","Embargo set by: Seth Robbins for item 107794 Lift date: 2020-09-27T16:30:34Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107794 Lift date: 2020-09-27T16:31:43Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107794 Lift date: 2020-09-27T16:34:29Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only Restriction Lifted for Item 107794 on 2020-09-28T09:15:16Z."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/101696"],"dc:language":["en"],"dc:rights":["Copyright 2018 Lauren Taylor Gates-Tanzer"],"dc:subject":["cFLIP","interferon, innate","immunity"],"dc:title":["Characterization of the anti-type I interferon effects of the cellular flice-like inhibitory protein (CFLIP)"],"dc:type":["text"],"thesis:degree_discipline":["Microbiology"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:40Z"}